Amgen (NASDAQ: AMGN) announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE